Cardiovascular consequences of recombinant DNA technology: interleukin-2

Ann Intern Med. 1988 Dec 15;109(12):933-5. doi: 10.7326/0003-4819-109-12-933.
No abstract available

Publication types

  • Research Support, U.S. Gov't, P.H.S.
  • Review

MeSH terms

  • Heart / physiopathology
  • Hemodynamics*
  • Humans
  • Hypotension / etiology
  • Interleukin-2 / adverse effects*
  • Killer Cells, Natural / immunology
  • Pulmonary Wedge Pressure
  • Shock, Septic / physiopathology

Substances

  • Interleukin-2